MIRM NASDAQ
Mirum Pharmaceuticals, Inc.
1W: -7.5%
1M: -16.9%
3M: -32.0%
YTD: +6.2%
1Y: +13.6%
3Y: +169.2%
5Y: +348.5%
$82.93
-0.99 (-1.18%)
Weekly Expected Move ±5.0%
$75
$79
$83
$87
$91
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.54
Bullish
4 bullish
0 neutral
1 bearish
Articles (7d)
5
Daily Sentiment (7 Days)
Articles (100)
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
MIRM Stock Gets Increased EPS Forecast from HC Wainwright
Mirum wins FDA approval for Atebrioz
Mirum falls despite meeting primary goal in phase 3 brelovitug study for hepatitis D
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Has Average Target Price of $137.31
Mirum Pharmaceuticals, Inc. $MIRM Stock Acquired by Corient Private Wealth LP
3 things to look out for on Friday
Bank of America Corp DE Makes New Investment in Mirum Pharmaceuticals, Inc. $MIRM
Engineers Gate Manager LP Raises Stock Position in Mirum Pharmaceuticals, Inc. $MIRM
Catalyst Watch: Trump-Xi in DC, Meta Connect, and McDonald's Investor Day
California State Teachers Retirement System Boosts Holdings in Mirum Pharmaceuticals, Inc. $MIRM
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
BlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRM
Deutsche Bank AG Purchases New Holdings in Mirum Pharmaceuticals, Inc. $MIRM
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down After Earnings Miss
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates
Arrowstreet Capital Limited Partnership Has $6.27 Million Stake in Mirum Pharmaceuticals, Inc. $MIRM
HC Wainwright Has Strong Estimate for MIRM FY2028 Earnings
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
Mirum and Incyte's zilurgisertib shows positive Phase 2 data in FOP
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
Mirum Pharma: A Rare Disease Growth Story to Watch
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
Mirum raises 2026 net product sales outlook to $660M-$680M as it targets year-end zilurgisertib launch
Mirum Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings
Mirum (MIRM) Q1 2026 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals GAAP EPS of -$13.43 misses by $13.06, revenue of $159.9M beats by $11.69M
Earnings Scheduled For May 6, 2026
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets
Baird reiterates Mirum Pharmaceuticals stock rating on positive trial data By Investing.com - Investing.com Canada
Mirum's Volixibat Meets Phase 2b Study Goal, Shows Significant Itch Reduction in PSC
Mirum’s Volixibat Succeeds in Phase 2b PSC Itch Trial - TipRanks
Why Mirum Pharmaceuticals Stock Is Sliding Now - TipRanks
Mirum's PSC itch drug cut symptoms in 2 weeks, FDA meeting set - Stock Titan
Volixibat eases cholestatic itch in PSC trial for Mirum (NASDAQ: MIRM) - Stock Titan
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Mirum schedules May 4 call to reveal PSC drug study topline data - Stock Titan
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
How (MIRM) Movements Inform Risk Allocation Models - Stock Traders Daily
Will Livmarli continue to aid Mirum's top line in Q1 earnings? - MSN
Mirum sets May 6 update on quarterly results and corporate progress - Stock Titan
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo! Finance Canada
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Shareholder Returns And Rare Disease Pipeline Progress
Mirum Pharmaceuticals (MIRM) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
MIRM Stock Price, Quote & Chart | MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) - ChartMill
Mirum HDV Trial Success Adds New Late Stage Growth Option
BlackRock (NASDAQ: MIRM) Holds 3.47M Shares, 5.7% Stake - Stock Titan
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Mirum shows 100% virologic response in one hepatitis delta arm; Phase 3 due H2 - Stock Titan
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?
Mirum pharmaceuticals director Saira Ramasastry sells $193,800 in stock - Investing.com
Mirum (MIRM) director uses options, sells 2,000 pre-planned shares - Stock Titan
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi‑Year Share Price Run?
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prediction: Buying This Biotech Stock Today Could Set You Up for Life
Prediction: Buying This Biotech Stock Today Could Set You Up for Life
Tudor Investment Corp ET AL Takes $2.03 Million Position in Mirum Pharmaceuticals, Inc. $MIRM
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its Strong Multi‑Year Share Price Run? - Yahoo Finance
ClearBridge SMID Cap Growth strategy initiates new positions, exits several in Q1
Egetis Appoints Tiago Nunes as Chief Medical Officer
18,710 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by SG Americas Securities LLC
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of “Moderate Buy” from Analysts
Mirum (MIRM) Q2 2025 Earnings Call Transcript
Mirum (MIRM) Q1 2025 Earnings Call Transcript
Mirum (MIRM) Q2 2025 Earnings Call Transcript
Mirum Pharma (MIRM) Earnings Call Transcript
Mirum (MIRM) Q1 2025 Earnings Call Transcript
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?
Mirum Pharmaceuticals (MIRM) Moves 5.1% Higher: Will This Strength Last?
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Strong Long Term Share Performance
Why Is Mirum Pharmaceuticals (MIRM) Down 3.6% Since Last Earnings Report?
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $3,769,800.30 in Stock
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
Aquatic Capital Management LLC Boosts Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM
Algert Global LLC Buys 31,250 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Moderate Buy” by Brokerages
Mirum Completes Enrollment & Screening in Liver Disease Studies
HC Wainwright Brokers Decrease Earnings Estimates for MIRM
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Volatile Trading On Common Stock Offering News - Yahoo Finance
Mirum Pharmaceuticals Stock Drops 15% After Share Offering. Analysts Still Target $120 - TIKR.com